Blog
RSS FeedPosted by Michael Wonder on 16 Apr 2019
Ribociclib in advanced breast cancer: survival benefits, but also severe side effects
15 April 2019 - In the overall view, an added benefit is not proven. ...
Posted by Michael Wonder on 28 Mar 2019
Single-payer drug pricing in a multi-payer health system: does Germany offer a model for the US?
22 March 2019 - An increasing number of presidential hopefuls, most recently Senator Kamala Harris, are proposing “single payer” or “Medicare ...
Posted by Michael Wonder on 26 Mar 2019
Numerous G-BA decisions on new medicines - five active substances with considerable added value
22 March 2019 - On Friday in Berlin, the Federal Joint Committee (G-BA) made numerous decisions on the extent of the ...
Posted by Michael Wonder on 05 Mar 2019
Methodological problems in the method used by IQWiG within early benefit assessment of new pharmaceuticals in Germany
5 March 2019 - The decision matrix applied by the IQWiG for the quantification of added benefit within the early benefit ...
Posted by Michael Wonder on 14 Feb 2019
Germany agrees on new pharmaceutical bill
13 February 2019 - On 30 January, the German government has agreed on a draft Act for more safety in ...
Posted by Michael Wonder on 03 Feb 2019
Erenumab in migraine: indication of a significant added benefit for certain patients
2 February 2019 - As a prophylaxis successful when other drug therapies are exhausted. ...
Posted by Michael Wonder on 29 Jan 2019
Identifying the need for good practices in health technology assessment-summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA
26 January 2019 - The systematic use of evidence to inform healthcare decisions, particularly health technology assessment, has gained increased recognition. ...
Posted by Michael Wonder on 23 Jan 2019
Citizens ask - scientists answer: the IQWiG sets four new topics for HTA reports
23 January 2019 - Citizens, patients and medical experts: selection of topics with a sense of proportion ...
Posted by Michael Wonder on 15 Jan 2019
Progressive squamous cell carcinoma of the head and neck: pembrolizumab prolongs survival
15 January 2019 - Only a few study participants were treated in compliance with the approval, therefore the extent of ...
Posted by Michael Wonder on 14 Jan 2019
Rexgenero's lead product REX-001 selected for the EUnetHTA prioritisation list for joint assessments
7 January 2019 - The Prioritisation list consists of just 14 medicinal products that have been identified as being of significant ...
Posted by Michael Wonder on 14 Jan 2019
EU Health Technology Assessment needs to move up a gear, says pressure group
9 January 2019 - The European Alliance for Personalised Medicine says it may seem to everyone that the whole debate ...
Posted by Michael Wonder on 14 Jan 2019
Mandatory or voluntary? A sticking point for European HTA
10 January 2019 - The long road to unified European Health Technology Assessment is continuing. ...
Posted by Michael Wonder on 10 Jan 2019
2018 in a nutshell: new edition with facts and graphics from the IQWiG
9 January 2019 - The focus of the 33-page brochure is information, overviews and charts on "Health Technology Assessment (HTA) ...
Posted by Michael Wonder on 17 Dec 2018
Novartis weighs reinsurance tie-up to fund ultra-expensive drugs
17 December 2018 - Could reinsures solve problem of high upfront costs of developing potentially life-saving treatments? ...
Posted by Michael Wonder on 08 Dec 2018
AMNOG as a learning system: new study on ingenol mebutate in actinic keratosis shows added benefit
3 December 2018 - Advantage over diclofenac in complete clearance of visible lesions / unclear sustainability of treatment effect ...